74.80MMarket Cap0.94P/E (TTM)
1.990High1.837Low89.59KVolume1.850Open1.890Pre Close171.78KTurnover0.24%Turnover Ratio1.42P/E (Static)37.78MShares3.87052wk High1.01P/B74.05MFloat Cap1.35052wk Low--Dividend TTM37.40MShs Float150.000Historical High--Div YieldTTM8.11%Amplitude1.150Historical Low1.917Avg Price1Lot Size
Scynexis Stock Forum
$Nanoviricides(NNVC.US)$
$Tenet Healthcare(THC.US)$
I want to watch these the most, I think, and now to find stuff in a different sector..
of Phase I anticipated in the second half of 2024
-- Clinical study reports for the FURI, CARES and NATURE trials in
refractory invasive fungal infections remain on track for delivery to GSK
in mid 2024, which would trigger a $10 million development milestone
payment to SCYNEXIS
-- SCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of
$94.2 million and projects a cash ...
NEWS
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. (SCYX) announces the presentation of preclinical efficacy data on SCY-247 at ECCMID 2024, focusing on addressing systemic fungal diseases and invasive fungal infections. SCY-247 shows promise in overcoming drug-resistant infections, particularly against Candida auris.
No comment yet